Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic treatment for prostate cancer.

A P Lyss1

  • 1Washington University School of Medicine, Division of Hematology/Oncology, St. Louis, Missouri.

The American Journal of Medicine
|December 1, 1987
PubMed
Summary

Systemic therapy for prostate cancer aims to palliate symptoms. Current hormonal and chemotherapeutic options, including combination regimens, have not yet proven superior to traditional treatments for improving survival or therapeutic index.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strategies for limiting the side effects of cancer pain therapy.

Seminars in oncology·1997
Same author

Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).

Clinical cancer research : an official journal of the American Association for Cancer Research·1995
Same author

A phase II trial of gallium nitrate in advanced previously untreated colorectal cancer.

Investigational new drugs·1993
Same author

Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1993
Same author

Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity.

Cancer investigation·1993
Same author

Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B.

Annals of oncology : official journal of the European Society for Medical Oncology·1992

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer is a significant cause of mortality in men.
  • Most patients present with subclinical systemic disease requiring palliative systemic therapy.
  • Traditional treatments include supplemental estrogens and castration.

Purpose of the Study:

  • To review the current landscape of systemic therapies for advanced prostate cancer.
  • To evaluate the efficacy of novel hormonal agents and chemotherapeutic regimens.
  • To define the optimal use of cytotoxic drugs in combination with hormonal therapy.

Main Methods:

  • Review of recent clinical studies and published data on prostate cancer systemic therapies.
  • Analysis of treatment outcomes for hormonal agents (GnRH analogues, estramustine) versus traditional modalities.
  • Evaluation of chemotherapy regimens, including single agents, multidrug regimens, and chemo-hormonal combinations.

Main Results:

  • New hormonal treatments have not demonstrated improved survival or therapeutic index over traditional options.
  • Chemotherapeutic agents show palliative efficacy but their optimal use is undefined.
  • Current evidence does not support combination chemotherapy being superior to single agents or chemo-hormonal therapy being superior to hormonal treatment alone.

Conclusions:

  • The optimal role of chemotherapy and novel hormonal agents in prostate cancer management remains to be defined.
  • Further research is needed to establish superior treatment strategies for advanced prostate cancer.
  • Current systemic therapies offer palliation, but significant improvements in survival are yet to be achieved with newer agents or combinations.

Related Experiment Videos